Reaction Details | |||
---|---|---|---|
Report a problem with these data | |||
Target | Mitogen-activated protein kinase 14 | ||
Ligand | BDBM50175751 | ||
Substrate/Competitor | n/a | ||
Meas. Tech. | ChEMBL_328207 (CHEMBL863946) | ||
IC50 | 5.2±n/a nM | ||
Citation | Bao, J; Hunt, JA; Miao, S; Rupprecht, KM; Stelmach, JE; Liu, L; Ruzek, RD; Sinclair, PJ; Pivnichny, JV; Hop, CE; Kumar, S; Zaller, DM; Shoop, WL; O'neill, EA; O'keefe, SJ; Thompson, CM; Cubbon, RM; Wang, R; Zhang, WX; Thompson, JE; Doherty, JB p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones. Bioorg Med Chem Lett16:64-8 (2005) [PubMed] Article | ||
More Info.: | Get all data from this article, Assay Method | ||
Mitogen-activated protein kinase 14 | |||
Name: | Mitogen-activated protein kinase 14 | ||
Synonyms: | CSAID-binding protein | CSBP | CSBP1 | CSBP2 | CSPB1 | Cytokine suppressive anti-inflammatory drug-binding protein | MAP kinase 14 | MAP kinase MXI2 | MAP kinase p38 alpha | MAPK 14 | MAPK14 | MAX-interacting protein 2 | MK14_HUMAN | MXI2 | Mitogen-activated protein kinase p38 alpha | SAPK2A | Stress-activated protein kinase 2a | p38 MAP kinase alpha/beta | ||
Type: | Serine/threonine-protein kinase | ||
Mol. Mass.: | 41286.76 | ||
Organism: | Homo sapiens (Human) | ||
Description: | Q16539 | ||
Residue: | 360 | ||
Sequence: |
| ||
BDBM50175751 | |||
n/a | |||
Name | BDBM50175751 | ||
Synonyms: | 7-(1-tert-butylpiperidin-4-yl)-1-(2,6-dichlorophenyl)-5-(2,4-difluorophenyl)-1,6-naphthyridin-2(1H)-one | CHEMBL199625 | ||
Type | Small organic molecule | ||
Emp. Form. | C29H27Cl2F2N3O | ||
Mol. Mass. | 542.447 | ||
SMILES | CC(C)(C)N1CCC(CC1)c1cc2n(-c3c(Cl)cccc3Cl)c(=O)ccc2c(n1)-c1ccc(F)cc1F |(18.46,6,;17.14,5.23,;17.91,3.89,;16.36,6.56,;15.8,4.46,;15.8,2.92,;14.47,2.15,;13.13,2.91,;13.13,4.45,;14.47,5.22,;11.8,2.14,;10.47,2.9,;9.13,2.13,;7.8,2.9,;7.8,4.43,;6.48,5.2,;5.14,4.43,;6.47,6.73,;7.81,7.52,;9.14,6.74,;9.14,5.2,;10.47,4.43,;6.46,2.13,;5.13,2.9,;6.47,.59,;7.8,-.19,;9.13,.59,;10.47,-.18,;11.81,.59,;10.47,-1.72,;9.13,-2.49,;9.13,-4.03,;10.47,-4.8,;10.47,-6.34,;11.81,-4.02,;11.8,-2.48,;13.13,-1.71,)| | ||
Structure |